| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/9780470572702.CH45 |
| P50 | author | Jeffery W. Kelly | Q6175781 |
| Johan F Paulsson | Q56073524 | ||
| R. Luke Wiseman | Q57429656 | ||
| Sungwook Choi | Q59662360 | ||
| Joel N Buxbaum | Q88718489 | ||
| P2093 | author name string | Evan T. Powers | |
| Steven M. Johnson | |||
| P2860 | cites work | Comparison of Lethal and Nonlethal Transthyretin Variants and Their Relationship to Amyloid Disease | Q41670698 |
| The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions | Q41696172 | ||
| Fibril in senile systemic amyloidosis is derived from normal transthyretin | Q24558717 | ||
| Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture | Q24626477 | ||
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates | Q24685634 | ||
| Rational design of potent human transthyretin amyloid disease inhibitors | Q27621990 | ||
| A comparative analysis of 23 structures of the amyloidogenic protein transthyretin | Q27627061 | ||
| An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured | Q27634853 | ||
| Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action | Q27641464 | ||
| Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization | Q27642438 | ||
| Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis | Q27642917 | ||
| Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. A lesson in the generation of transgenic models of diseases involving oligomeric proteins | Q27649069 | ||
| Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors | Q27649376 | ||
| Structural insight into pH-induced conformational changes within the native human transthyretin tetramer | Q27651370 | ||
| Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies † | Q27652272 | ||
| Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A | Q27729158 | ||
| Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein | Q27730236 | ||
| Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis | Q27734827 | ||
| Inhibiting transthyretin conformational changes that lead to amyloid fibril formation | Q27765742 | ||
| Adapting proteostasis for disease intervention | Q28131818 | ||
| A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves | Q28207316 | ||
| Protein folding and misfolding | Q28235199 | ||
| Folding proteins in fatal ways | Q28235206 | ||
| A primer of amyloid nomenclature | Q28241008 | ||
| Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP) | Q28370305 | ||
| The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways | Q41728317 | ||
| Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy | Q43740028 | ||
| Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors | Q43849715 | ||
| Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry | Q44022725 | ||
| Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy | Q44603656 | ||
| Protofilaments, filaments, ribbons, and fibrils from peptidomimetic self-assembly: implications for amyloid fibril formation and materials science | Q44678447 | ||
| A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation | Q44765894 | ||
| Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants | Q44767199 | ||
| Transthyretin is involved in depression-like behaviour and exploratory activity | Q44792315 | ||
| Transthyretin aggregation under partially denaturing conditions is a downhill polymerization | Q44925089 | ||
| Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. | Q45041133 | ||
| Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors | Q45248277 | ||
| Gene therapy: lessons learned from liver transplantation for transthyretin-amyloidosis | Q45879595 | ||
| Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. | Q46251178 | ||
| Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation | Q46301078 | ||
| Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis | Q46380708 | ||
| Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation | Q46407641 | ||
| Kinetic stabilization of an oligomeric protein by a single ligand binding event | Q46425326 | ||
| Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state | Q46470305 | ||
| Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study | Q46645719 | ||
| Transthyretin isoleucine-122 mutation in African and American blacks | Q46808325 | ||
| Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution | Q47983806 | ||
| Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes | Q48087328 | ||
| The ups and downs of Abeta | Q48475770 | ||
| Neurodegenerative disease: amyloid pores from pathogenic mutations | Q48544171 | ||
| Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils | Q48683371 | ||
| Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice | Q48846848 | ||
| Analysis of protein aggregation kinetics. | Q52143609 | ||
| Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). | Q52807508 | ||
| Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid | Q52883960 | ||
| Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. | Q53245545 | ||
| Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. | Q54160889 | ||
| Familial amyloid polyneuropathy | Q56031909 | ||
| The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke | Q56944340 | ||
| Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease | Q57240374 | ||
| Liver Transplantation Does Not Prevent the Development of Life-Threatening Arrhythmia in Familial Amyloidotic Polyneuropathy, Portuguese-Type (ATTR Val30Met) Patients | Q57259453 | ||
| Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis | Q57424500 | ||
| Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix | Q57945110 | ||
| Transthyretin enhances nerve regeneration | Q58154194 | ||
| No Evidence Of De Novo Amyloidosis In Recipients Of Domino Liver Transplantation: 12 To 40 (Mean 24) Month Follow-Up | Q58186102 | ||
| Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP) (TTR Met 30) | Q58261278 | ||
| In vivostabilization of mutant human transthyretin in transgenic mice | Q58274802 | ||
| Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award | Q28609126 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins | Q29547593 | ||
| Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective | Q29614702 | ||
| A beta oligomers - a decade of discovery | Q29615152 | ||
| Opposing activities protect against age-onset proteotoxicity | Q29619758 | ||
| Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin | Q30164014 | ||
| Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation | Q30779129 | ||
| The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation | Q33272109 | ||
| Cell division and apoptosis in the adult neural stem cell niche are differentially affected in transthyretin null mice | Q33288004 | ||
| The transthyretin gene is expressed in human and rodent dorsal root ganglia | Q33327859 | ||
| Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid | Q33872413 | ||
| The genetics of the amyloidoses | Q33896126 | ||
| Nucleated conformational conversion and the replication of conformational information by a prion determinant | Q33915141 | ||
| Liver transplantation for hereditary transthyretin amyloidosis. | Q33927163 | ||
| Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro | Q33949040 | ||
| The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis | Q33952780 | ||
| Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths | Q34018579 | ||
| Transmissibility of systemic amyloidosis by a prion-like mechanism | Q34068073 | ||
| Trans-suppression of misfolding in an amyloid disease. | Q34092993 | ||
| Prevention of transthyretin amyloid disease by changing protein misfolding energetics. | Q34174171 | ||
| Pathogenesis, diagnosis and treatment of systemic amyloidosis | Q34190813 | ||
| D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? | Q34201956 | ||
| Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro | Q34252457 | ||
| Therapeutic approaches to protein-misfolding diseases | Q34285075 | ||
| Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. | Q34334873 | ||
| Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity | Q34378271 | ||
| The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid | Q34380911 | ||
| Alternative conformations of amyloidogenic proteins govern their behavior | Q34387876 | ||
| The biological and chemical basis for tissue-selective amyloid disease | Q34410187 | ||
| Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans | Q34415207 | ||
| Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets? | Q34423072 | ||
| Transthyretin: a review from a structural perspective. | Q34427841 | ||
| Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity | Q34443897 | ||
| The pathway by which the tetrameric protein transthyretin dissociates. | Q34469219 | ||
| Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. | Q34477195 | ||
| Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis | Q34581917 | ||
| Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. | Q34592571 | ||
| Therapeutic strategies for human amyloid diseases | Q34743288 | ||
| The most infectious prion protein particles. | Q34805737 | ||
| Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses | Q34831241 | ||
| Transthyretin in fish: state of the art. | Q35054934 | ||
| Alpha(1)-antitrypsin deficiency, liver disease and emphysema | Q35097639 | ||
| Hereditary transthyretin amyloidosis from a Scandinavian perspective. | Q35203818 | ||
| A role for destabilizing amino acid replacements in light-chain amyloidosis | Q35458844 | ||
| DNA variation and brain region-specific expression profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. | Q35751646 | ||
| Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system | Q35764307 | ||
| Intraneuronal Abeta42 accumulation in human brain. | Q35793325 | ||
| Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma | Q35885902 | ||
| Liver transplantation in transthyretin-related familial amyloid polyneuropathy | Q35887737 | ||
| Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss | Q35918370 | ||
| Homing in on intracellular Abeta? | Q36062369 | ||
| The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba | Q36227174 | ||
| Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation | Q36303237 | ||
| Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity | Q36497488 | ||
| Small molecule oxidation products trigger disease-associated protein misfolding. | Q36596598 | ||
| Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. | Q36640504 | ||
| Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly | Q36736931 | ||
| Folding versus aggregation: polypeptide conformations on competing pathways | Q36858313 | ||
| Inhibiting transthyretin amyloid fibril formation via protein stabilization | Q37082709 | ||
| Heparin accelerates gelsolin amyloidogenesis | Q37132636 | ||
| Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. | Q37153865 | ||
| Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization | Q37369949 | ||
| Metabolite-initiated protein misfolding may trigger Alzheimer's disease | Q37414917 | ||
| Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity | Q38314199 | ||
| A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population | Q39723184 | ||
| Alzheimer's Abeta peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity. Evidence for a common low-abundance toxic structure(s)? | Q40035906 | ||
| The cerebral expression of plasma protein genes in different species | Q40525379 | ||
| Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface | Q40741466 | ||
| A glimpse of a possible amyloidogenic intermediate of transthyretin | Q40750422 | ||
| Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? | Q40918121 | ||
| For protein misassembly, it's the "I" decade | Q41106314 | ||
| P304 | page(s) | 967-1003 | |
| P577 | publication date | 2010-07-02 | |
| P1476 | title | Understanding and Ameliorating the TTR Amyloidoses |
Search more.